{"id":56295,"date":"2026-02-04T22:59:57","date_gmt":"2026-02-04T14:59:57","guid":{"rendered":"https:\/\/flcube.com\/?p=56295"},"modified":"2026-02-04T22:59:58","modified_gmt":"2026-02-04T14:59:58","slug":"marubeni-launches-xenleta-in-china-after-complex-licensing-journey","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56295","title":{"rendered":"Marubeni Launches Xenleta in China After Complex Licensing Journey"},"content":{"rendered":"\n<p><strong>Marubeni Pharmaceuticals (China) Co., Ltd.<\/strong> (formerly Sumitomo Pharma China) announced the initiation of commercialization for <strong>Xenleta (lefamulin acetate) in China<\/strong>, with a market launch slated for <strong>April\u202f2026<\/strong>. The first\u2011in\u2011class pleuromutilin antibiotic for community\u2011acquired pneumonia (CAP) concludes a multi\u2011year licensing journey involving <strong>Nabriva, Sinovant Sciences, and Sumitomo Pharma<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-licensing-history-evolution\">Licensing History Evolution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Year<\/th><th>Milestone<\/th><th>Parties Involved<\/th><\/tr><\/thead><tbody><tr><td><strong>2018<\/strong><\/td><td>Nabriva licenses Greater China rights to <strong>Sinovant Sciences<\/strong><\/td><td>Nabriva \u2192 Sinovant (CITIC\/Roivant JV)<\/td><\/tr><tr><td><strong>May\u202f2021<\/strong><\/td><td>Sinovant assigns license to <strong>Sumitomo (Suzhou)<\/strong><\/td><td>Sinovant \u2192 Sumitomo (terms unchanged)<\/td><\/tr><tr><td><strong>2023<\/strong><\/td><td>Sumitomo Pharma acquires full rights from Nabriva<\/td><td>Sumitomo \u2190 Nabriva (Mainland China, HK, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Nov\u202f2023<\/strong><\/td><td>Category\u202f5.1 lefamulin approved for marketing<\/td><td>Sumitomo Pharma (Suzhou) submission<\/td><\/tr><tr><td><strong>Jun\u202f2025<\/strong><\/td><td>Category\u202f4 chemical drug approval (local transfer)<\/td><td>Sumitomo Pharma Group submission<\/td><\/tr><tr><td><strong>Apr\u202f2026<\/strong><\/td><td><strong>Commercial launch<\/strong> (planned)<\/td><td>Marubeni Pharmaceuticals (China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-market-position\">Product Profile &amp; Market Position<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Xenleta (lefamulin acetate)<\/td><\/tr><tr><td><strong>Originator<\/strong><\/td><td>Nabriva Therapeutics<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>First\u2011in\u2011class pleuromutilin antibiotic<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Community\u2011acquired pneumonia (CAP)<\/td><\/tr><tr><td><strong>US Approval<\/strong><\/td><td>FDA approved 2019<\/td><\/tr><tr><td><strong>China Regulatory Status<\/strong><\/td><td>Category\u202f4 chemical drug (locally transferred)<\/td><\/tr><tr><td><strong>Launch Timeline<\/strong><\/td><td>April\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China CAP Market:<\/strong> Valued at <strong>\u00a515\u202fbillion<\/strong> : (~US$2.1\u202fbillion) in 2025; novel antibiotics represent <strong>~8%<\/strong> : of market but growing due to resistance concerns<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>fluoroquinolones<\/strong> and <strong>macrolides<\/strong>; Xenleta\u2019s novel mechanism offers advantage against resistant pathogens<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Marubeni\u2019s launch completes the licensing circle, leveraging Sumitomo\u2019s established China infrastructure; positions company as a credible player in anti\u2011infectives<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a5200\u2013350\u202fmillion<\/strong> (US$28\u201349\u202fmillion) peak annual sales by 2028, assuming 5% share of premium CAP segment<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Distribution agreements with major hospital groups to be finalized <strong>Q1\u202f2026<\/strong>; medical affairs team to conduct physician education programs<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration, and revenue projections for Xenleta. Actual results may differ due to competitive dynamics, hospital formulary access, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[40,4591,577],"class_list":["post-56295","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-market-launch","tag-marubeni-pharmaceuticals","tag-sumitomo-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Marubeni Launches Xenleta in China After Complex Licensing Journey - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for Xenleta (lefamulin acetate) in China, with a market launch slated for April\u202f2026. The first\u2011in\u2011class pleuromutilin antibiotic for community\u2011acquired pneumonia (CAP) concludes a multi\u2011year licensing journey involving Nabriva, Sinovant Sciences, and Sumitomo Pharma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56295\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marubeni Launches Xenleta in China After Complex Licensing Journey\" \/>\n<meta property=\"og:description\" content=\"Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for Xenleta (lefamulin acetate) in China, with a market launch slated for April\u202f2026. The first\u2011in\u2011class pleuromutilin antibiotic for community\u2011acquired pneumonia (CAP) concludes a multi\u2011year licensing journey involving Nabriva, Sinovant Sciences, and Sumitomo Pharma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56295\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T14:59:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T14:59:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56295#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56295\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Marubeni Launches Xenleta in China After Complex Licensing Journey\",\"datePublished\":\"2026-02-04T14:59:57+00:00\",\"dateModified\":\"2026-02-04T14:59:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56295\"},\"wordCount\":313,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Market launch\",\"Marubeni Pharmaceuticals\",\"Sumitomo Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56295#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56295\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56295\",\"name\":\"Marubeni Launches Xenleta in China After Complex Licensing Journey - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-04T14:59:57+00:00\",\"dateModified\":\"2026-02-04T14:59:58+00:00\",\"description\":\"Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for Xenleta (lefamulin acetate) in China, with a market launch slated for April\u202f2026. The first\u2011in\u2011class pleuromutilin antibiotic for community\u2011acquired pneumonia (CAP) concludes a multi\u2011year licensing journey involving Nabriva, Sinovant Sciences, and Sumitomo Pharma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56295#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56295\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56295#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marubeni Launches Xenleta in China After Complex Licensing Journey\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Marubeni Launches Xenleta in China After Complex Licensing Journey - Insight, China&#039;s Pharmaceutical Industry","description":"Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for Xenleta (lefamulin acetate) in China, with a market launch slated for April\u202f2026. The first\u2011in\u2011class pleuromutilin antibiotic for community\u2011acquired pneumonia (CAP) concludes a multi\u2011year licensing journey involving Nabriva, Sinovant Sciences, and Sumitomo Pharma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56295","og_locale":"en_US","og_type":"article","og_title":"Marubeni Launches Xenleta in China After Complex Licensing Journey","og_description":"Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for Xenleta (lefamulin acetate) in China, with a market launch slated for April\u202f2026. The first\u2011in\u2011class pleuromutilin antibiotic for community\u2011acquired pneumonia (CAP) concludes a multi\u2011year licensing journey involving Nabriva, Sinovant Sciences, and Sumitomo Pharma.","og_url":"https:\/\/flcube.com\/?p=56295","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T14:59:57+00:00","article_modified_time":"2026-02-04T14:59:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56295#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56295"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Marubeni Launches Xenleta in China After Complex Licensing Journey","datePublished":"2026-02-04T14:59:57+00:00","dateModified":"2026-02-04T14:59:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56295"},"wordCount":313,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Market launch","Marubeni Pharmaceuticals","Sumitomo Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56295#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56295","url":"https:\/\/flcube.com\/?p=56295","name":"Marubeni Launches Xenleta in China After Complex Licensing Journey - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-04T14:59:57+00:00","dateModified":"2026-02-04T14:59:58+00:00","description":"Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for Xenleta (lefamulin acetate) in China, with a market launch slated for April\u202f2026. The first\u2011in\u2011class pleuromutilin antibiotic for community\u2011acquired pneumonia (CAP) concludes a multi\u2011year licensing journey involving Nabriva, Sinovant Sciences, and Sumitomo Pharma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56295#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56295"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56295#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Marubeni Launches Xenleta in China After Complex Licensing Journey"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56295"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56295\/revisions"}],"predecessor-version":[{"id":56298,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56295\/revisions\/56298"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}